Recently, Novo Nordisk announced that the FDA has issued a Complete Response Letter regarding the Biologics License Application for once-weekly basal insulin icodec intended for diabetes mellitus treatment
Acts as a signal and carrier peptide, stimulating skins own healing and maintenance pathways
These include: Dulaglutide (Trulicity) : Once-weekly injection with a single-dose pen featuring an automatic injection mechanism Semaglutide (Ozempic) : Once-weekly administration with dose escalation from 0.25 mg to maintenance doses of 0.5 mg, 1 mg, or 2 mg Exenatide extended-release (Bydureon BCise) : Once-weekly microsphere suspension requiring resuspension before injection Liraglutide (Victoza) : Once-daily injection available in a multi-dose pen For weight management, semaglutide 2.4 mg (Wegovy) and liraglutide 3.0 mg (Saxenda) are specifically FDA-approved
Budget-conscious researchers seeking to extend their supply while still achieving meaningful results also favor this range
So if stomach pain is an adverse event, it could be graded as mild, moderate, severe (life-threatening and fatal are also grades on this scale)
To date, studies have reported minimal adverse effects at typical research-level dosages